DORA-22

• UNSPSC Description:

  DORA-22 is an orally active dual orexinergic receptor antagonist, and improves the sleep disruption and memory impairment. DORA-22 can be used for study of insomnia[1][2].

• Target Antigen:

  Orexin Receptor (OX Receptor)

• Type:

  Reference compound

• Related Pathways:

  GPCR/G Protein;Neuronal Signaling

• Applications:

  Neuroscience-Neuromodulation

• Field of Research:

  Neurological Disease

• Assay Protocol:

  https://www.medchemexpress.com/dora-22.html

• Smiles:

  FC1=CC(C(N2C[C@H](COC3=NC=C(F)C=C3)CC[C@H]2C)=O)=C(C4=NC=CC=N4)C=C1

• Molecular Weight:

  424.44

• References & Citations:

  [1]Gamble MC, et al. The dual orexinergic receptor antagonist DORA-22 improves the sleep disruption and memory impairment produced by a rodent insomnia model. Sleep. 2020;43(3):zsz241. |[2]Lin Y, Ret al. Positive allosteric adenosine A2A receptor modulation suppresses insomnia associated with mania- and schizophrenia-like behaviors in mice. Front Pharmacol. 2023;14:1138666. Published 2023 Apr 19.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  1088991-95-0